卵巢癌铂耐药:PFI“二分法”的局限性与可能的改进  

Platinum Resistance in Ovarian Cancer:Limitations of PFI Binary Classification and Potential Improvements

作　　者：李笑宇 张楠[1] 狄文[1] LI Xiaoyu;ZHANG Nan;DI Wen(Department of Obstetrics and Gynecology,Renji Hospital,School of Medicine,Shanghai Jiaotong University,Shanghai Key Laboratory of Gynecologic Oncology,Renji Hospital,School of Medicine,Shanghai Jiaotong University,State Key Laboratory of Systems Medicine for Cancer,Renji Hospital,School of Medicine,Shanghai Jiaotong University,Shanghai 200127,China)

机构地区：[1]上海交通大学医学院附属仁济医院妇产科,上海市妇科肿瘤重点实验室,肿瘤系统医学全国重点实验室,上海200127

出　　处：《肿瘤防治研究》2024年第10期813-819,共7页Cancer Research on Prevention and Treatment

摘　　要：卵巢癌是一种较为常见的妇科恶性肿瘤,临床上主要通过无铂间期将复发性卵巢癌分为铂耐药性与铂敏感性,分别对应不同的治疗方式及预后。铂耐药性卵巢癌的治疗十分困难,随着研究的深入,有学者提出根据无铂间期的“二分法”存在一定局限性。因此,本文将对复发性卵巢癌的分类、铂耐药性卵巢癌的治疗困境、无铂间期“二分法”的局限性与新的分类思路作一综述,帮助临床工作者更好地了解卵巢癌分类方面的研究进展,从而制定更加有效的治疗策略。Ovarian cancer is a common gynecologic malignancy.In clinical practice,recurrent ovarian cancer is mainly classified into two categories on the basis of platinum-free interval,platinum-resistant and platinumsensitive,corresponding to different treatment modalities and prognoses.The treatment of platinum-resistant ovarian cancer is challenging.Some scholars have pointed out limitations in the binary classification of platinum-free interval.In this article,the classification of recurrent ovarian cancer,the treatment challenges of platinum-resistant ovarian cancer,the limitations of the platinum-free interval binary classification,and new classification perspectives were reviewed to help physicians enhance their understanding on the research progress in ovarian cancer classification and develop more effective treatment strategies.

关 键 词：卵巢癌 铂耐药 无铂间期 分类 

分 类 号：R737.31[医药卫生—肿瘤]